Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4259-4266

  Friedlos, Frank ^a   Lehouritis, Panos ^a   Ogilvie, Lesley ^a   Hedley, Douglas ^a   Davies, Lawrence ^a   Bermudes, David ^b   King, Ivan ^b   Martin, Jan ^a   Marais, Richard ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; CARBOXYPEPTIDASE G2; PRODRUG; GAMMA GLUTAMYL HYDROLASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL VIABILITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; COLON CARCINOMA; COLONY FORMING UNIT; CYTOPLASM; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; GENE VECTOR; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; SUICIDE GENE THERAPY; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; COLON TUMOR; FLOW CYTOMETRY; GENE THERAPY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; FLOW CYTOMETRY; GAMMA-GLUTAMYL HYDROLASE; GENE THERAPY; GENETIC VECTORS; HUMANS; MELANOMA; MICE; NEOPLASM TRANSPLANTATION; PRODRUGS; SALMONELLA TYPHIMURIUM;

EID: 48249141464     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4800     Document Type: Article

References (40)

1. Springer CJ. Suicide gene therapy methods and reviews. Totowa (NJ): Humana Press; 2004.
2. Hedley D, Ogilvie L, Springer C. Carboxypeptidase G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer 2007;7:870-9.
3. Theys J, Pennington O, Dubois L, et al. Repeated cycles of Clostridium -directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 2006;95:1212-9.
4. Barbe S, Van Mellaert L, Anne J. The use of clostridial spores for cancer treatment. J Appl Microbiol 2006; 101:571-8.
5. Dang LH, Bettegowda C, Huso DL. Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001;98:15155-60.
6. Bhatnagar PK, Awasthi A, Nomellini JF, Smit J, Suresh MR. Anti-tumor effects of the bacterium Caulobacter crescentus in murine tumor models. Cancer Biol Ther 2006;5:485-91.
7. Clairmont C, Bermudes D, Low KB, et al. VNP20009, a genetically modified Salmonella typhimurium: anti-tumor efficacy, toxicology, and biodistribution in preclinical models. Clin Cancer Res 1999;5:3830.
8. Low KB, Ittensohn M, Luo X, et al. Construction of VNP20009, a novel, genetically stable antibioticsensitive strain of tumor-targeting Salmonella for parenteral administration in humans. Methods Mol Med 2004;90:47-60.
9. Zhang L, Gao LF, Zhao LJ, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 2007;67:5859-64.
10. Low KB, Ittensohn M, LeT, et al. Lipid A mutant Salmonella with suppressed virulence and TNF α induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37-41.
11. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997;57:4537-44.
12. Lee KC, Zheng LM, Margitich D, Almassian B, King I. Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent. Int J Toxicol 2001;20:207-17.
13. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142-52.
14. Avogadri F, Martinoli C, Petrovska L, et al. Cancer immunotherapy based on killing of Salmonella infected tumor cells. Cancer Res 2005;65:3920-7.
15. Thamm DH, Kurzman ID, King I, et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 2005; 11:4827-34.
16. Minton NP, Atkinson T, Sherwood RF. Molecularcloning of the Pseudomonas carboxypeptidase-G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 1983;156:1222-7.
17. Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, et al. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT. J Med Chem 2003;46:1690-705.
18. Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, et al. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. J Med Chem 1998;41: 5297-309.
19. Niculescu-Duvaz I, Friedlos F, Niculescu-Duvaz D, Davies L, Springer CJ. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPTand GDEPT). Anticancer Drug Des 1999;14:517-38.
20. Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos F, et al. Self-immolative anthracycline prodrugs for suicide gene therapy. J Med Chem 1999;42:2485-9.
21. Niculescu-Duvaz I, Scanlon I, Niculescu-Duvaz D, et al. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. J Med Chem 2004;47:2651-8.
22. Davies LC, Friedlos F, Hedley D, et al. Novel fluorinated prodrugs for activation by carboxypeptidase G 2 showing good in vivo anti-tumor activity in gene directed enzyme prodrug therapy (GDEPT). J Med Chem 2005;48:5321-8.
23. Friedlos F, Davies L, Scanlon I, et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res 2002;62:1724-9.
24. Francis RJ, Sharma SK, Springer CJ, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal cancer or other CEA producing tumours. Br J Cancer 2002; 87:600-7.
25. Mayer A, Francis RJ, Sharma SK, et al. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anticarcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 2006;12:6509-16.
26. Schepelmann S, Hallenbeck P, Ogilvie LM, et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res 2005; 65:5003-8.
27. Schepelmann S, Ogilvie LM, Hedley D, et al. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2 Cancer Res 2007;67:4949-55.
28. Marais R, Spooner R, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination Cancer Res 1996;56:4735-42.
29. Marais R, Spooner R, Stribbling SM, Light Y. Martin J. Springer CJ. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy Nat Biotechnol 1997;15:1373-7.
30. Stribbling SM, Friedlos F, Martin J, et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum GeneTher 2000;11:285-92.
31. Springer CJ. CMDA. Drugs Future 1993;18 212-5.
32. Springer CJ, Dowell R, Burke RJ, et al. Optimization of alkyating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767P) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1995;38: 5051-65.
33. Springer CJ. Niculescu-Duvaz I. Pedley RB. Novel prodrugs of alkylating agents derived from 2-fluoroand 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J Med Chem 1994;37: 2361-70.
34. Amann E. Ochs B, Abel KJ. Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli. Gene 1988;69: 301-15.
35. Minton NP, Atkinson T, Bruton CJ, Sherwood RF The complete nucleotide sequence of the Pseudomonas gene coding for carboxypeptidase G2. Gene 1984;31:31-8.
36. Bolla JM, Lazdunski C, Inouye M, Pages JM. Export and secretion of overproduced Ompa-β-lactamase in Escherichia coli. FEBS Lett 1987;224:213-8.
37. Galan JE, Nakayama K, Curtiss R. Cloning and characterization of the Asd gene of Salmonella typhimurium-use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 1990; 94:29-35.
38. Workman P, Twentyman P, Balkwill F. et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer1998;77:1-10.
39. Sherwood RF, Melton RG, Alwan SM, Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp strain Rs-16-use of a novel triazine dye affinity method. Eur J Biochem 1985;148: 447-53.
40. Roberts JJ, Friedlos F, Scott D, Ormerod MG, Rawlings C J. The unique sensitivity of Walker rat tumor cells to difunctional agents is associated with a failure to recover from inhibition of DNA synthesis and increased chromosome damage. Mutat Res 1986;166:169-81.